31 results about "Bone morphogenetic protein 7" patented technology

Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and/or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s).

A mesenchymal stem cell extract and its use are provided, wherein the mesenchymal stem cell extract comprises a trophic factor(s), such as bone morphogenetic protein-7 (BMP-7), stromal cell-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), C-X-C chemokine receptor type-4 (CXCR4), brain-derived neurotrophic factor (BDNF), and/or interleukin-17 (IL-17), and wherein the extract is especially suitable for repairing skin aging.

Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.

A drug for promoting bone morphogenetie protein expression to accelerate fracture healing is prepared by carboxymethylation of sodium alginate. The drug is prepared by the steps: adding 15 g of a sodium hydroxide liquid (2 mol/L) into each 100 g of sodium alginate, mixing uniformly, and stirring for 0.5 h at the temperature of 35 DEG C; then adding a mixture of 20 g of monochloroacetic acid and 20 g of sodium hydroxide according to each 100 g of sodium alginate, carrying out a stirring reaction for 3 h under a condition of the temperature of 70-80 DEG C, and thus obtaining a carboxymethyl sodium alginate resultant. The drug also can be prepared by in a 95% ethanol solution, taking sodium alginate, sodium hydroxide and monochloroacetic acid and carrying out a one-pot frying method, and particularly is prepared by the steps: according to the ratio of mass, mass and volume of 1:0.35:0.30, taking sodium alginate, sodium hydroxide and monochloroacetic acid, putting into the 95 vol% ethanol solution with the volume of 2 times that of the mixture, and carrying out a reaction under conditions of the etherification temperature of 50 DEG C and the etherification time of 3 h; and washing the reaction product with 95% ethanol, precipitating for 24 h, drying the resultant, and thus obtaining the carboxymethyl sodium alginate resultant. The obtained carboxymethyl sodium alginate is capable of promoting the bone morphogenetie protein expression, and is used in drugs for treating and preventing fractures, bone nonunion, osteonecrosis of the femoral head, and osteoporosis.

The invention discloses a dissoluble preparation of bone morphogenetic protein-7, which contains bone morphogenetic protein-7, L-arginine or/and urea, protein stabilizer and water for injection, and has the advantages that the solubility is high, and deposition does not occur in the serum, and the consistence can reach 0.2-1.0 mg/ml. The dissoluble preparation of bone morphogenetic protein-7 of the invention can be used for curing clinical kidney disease and vascular calcification, and for curing resumption of cerebral apoplexy, and liver and lung fibrosis as well.